首页> Expert opinion on investigational drugs> CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction.

CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction.

导出 LinkOut

翻译打印收藏纠错

第一作者： Davide,Capodanno

第一单位： a Division of Cardiology , CAST, P.O. "Rodolico", Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", University of Catania , Catania , Italy.

作者： Davide,Capodanno ^[1] ; Roxana,Mehran ^[2] ; C Michael,Gibson ^[3] ; Dominick J,Angiolillo ^[4]

作者单位： a Division of Cardiology , CAST, P.O. "Rodolico", Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", University of Catania , Catania , Italy. ^[1] b Columbia University Medical Center and the Cardiovascular Research Foundation , New York , NY , USA. ^[2] c The PERFUSE Study Group, Cardiovascular Division, Department of Medicine , Beth Israel Deaconess Medical, Harvard Medical School , Boston , MA , USA. ^[3] d Division of Cardiology , University of Florida College of Medicine , Jacksonville , FL , USA. ^[4]

关键词 AEGIS-I trial CSL112 HDL High-density lipoprotein MACE apoA-I major adverse cardiac events myocardial infarction